OakChart

Molecular Partners AG ADR

MOLNHealthcare·Biotechnology·Switzerland·Micro·NASD·Nov 11 • 3:53 PM ET

3.09+0.00 (0.09%)
2026-11-11 23:35 CET
Market cap
118.46 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-64.17 USD m
Free cash flow, TTM
-58.21 USD m
EPS diluted, TTM
-1.69
P/E
-
Compare

Price

MOLN against its 20, 50 and 200-day averages
2050200beatearnings
3.003.504.004.5023K47KVolumeApr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MOLNclose 3.0920-day 3.4950-day 3.89200-day 4.143.09

42.4% under the 52-week high of 5.36 on 27 Feb 2026. 52-week low 3.09 on 3 Nov 2026. Last 15 sessions, 23.3% high to low

Volume 0.23× normal · the line is the 50-bar volume average

Profile

MOLN
52-week range, 0% of the way up
3.095.36

Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274, and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Pluckthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

Employees149
IPOJun 16, 2021
Beta1.16
ATR, 14d0.19
Rel volume0.23
Short float0.00%
Insider own0.28%
Inst own9.37%

Snapshot

6 groups

Valuation

Index-
Market Cap118.47M
Enterprise Value52.89M
Income-64.17M
Sales0.00M
Book/sh1.58
Cash/sh1.80
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees149
IPOJun 16, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.95
P/C1.72
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio6.46
Current Ratio6.46
Debt/Eq0.05
LT Debt/Eq0.03
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.69
EPS next Y-1.49
EPS next Q-0.44
EPS this Y18.93%
EPS next Y12.65%
EPS next 5Y9.82%
EPS past 3/5Y- 5.73%
Sales past 3/5Y- -
EPS Y/Y TTM11.22%
Sales Y/Y TTM-100.00%
EPS Q/Q4.91%
Sales Q/Q-
EarningsOct 29 BMO
EPS/Sales Surpr.0.00% -

Ownership

Insider Own0.28%
Insider Trans0.00%
Inst Own9.37%
Inst Trans-0.68%
ROA-58.81%
ROE-71.01%
ROIC-102.66%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-11.41%
SMA50-20.61%
SMA200-25.40%
Trades-

Technical

Shs Outstand38.34M
Shs Float38.23M
Short Float0.00%
Short Ratio0.00
Short Interest0.00M
52W High5.36 -42.35%
52W Low3.09 0.00%
Volatility3.67% 3.67%
ATR (14)0.19
RSI (14)33.43
Beta1.16
Rel Volume0.23
Avg Volume2.02K
Volume463

Performance

Perf Week-4.83%
Perf Month-15.80%
Perf Quarter-26.60%
Perf Half Y-22.75%
Perf YTD-29.11%
Perf Year-23.33%
Perf 3Y-25.50%
Perf 5Y-78.89%
Perf 10Y-
Recom1.29
Target Price11.13
Prev Close3.09
Price3.09
Change %0.09%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Jan 27, 2026InitiatedHH.C. WainwrightBuy$13+320.7%
Aug 30, 2022DowngradeRRBC Capital MktsOutperform → Sector Perform
Aug 29, 2022DowngradeSSVB LeerinkOutperform → Mkt Perform$30 → $8+158.9%
May 25, 2022UpgradeCCredit SuisseUnderperform → Neutral
Apr 27, 2022DowngradeCCredit SuisseNeutral → Underperform
Jul 13, 2021InitiatedCCowenOutperform$50+1,518.1%
Jul 12, 2021ResumedSSVB LeerinkOutperform$36+1,065.0%

Peers

Mkt cap
TickerCompanyMkt cap
CATXPerspective Therapeutics Inc99.65M
TLXTelix Pharmaceuticals Ltd ADR3.31B
JANXJanux Therapeutics Inc758.06M
MGNXMacrogenics Inc147.78M
CLRBCellectar Biosciences Inc11.44M
XNCRXencor Inc3.00B
ZLABZai Lab Limited ADR2.98B
IMTXImmatics N.V1.00B
ZYMEZymeworks BC Inc2.02B
LNTHLantheus Holdings Inc6.64B

News

latest 14 of 200
  • Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026 (GlobeNewswire)
  • Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026 (GlobeNewswire)
  • Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy (GlobeNewswire)
  • Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70 (GlobeNewswire)
  • Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study (GlobeNewswire)
  • Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma (GlobeNewswire)
  • Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference (GlobeNewswire)
  • Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics (GlobeNewswire)
  • Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712 (GlobeNewswire)
  • Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1 (GlobeNewswire)
  • Molecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation Summit (GlobeNewswire)
  • Eckert & Ziegler SE (XTER:EUZ) Q1 2026 Earnings Call Highlights: Strong Medical Division ... (GuruFocus.com)
  • Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317 (GlobeNewswire)
  • Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-29-0.416-0.416-0.3760.000.002
2026Q22026-08-25-0.434-0.433-0.4480.000.002
2026Q12026-05-12-0.433-0.434-0.4470.000.003
2025Q42026-03-12-0.430-0.400-0.4230.000.003
2025Q32025-10-30-0.414-0.460-0.3960.000.001
2025Q22025-08-25-0.684-0.475-0.6600.000.001
2025Q12025-05-15-0.542-0.421-0.5060.000.002
2024Q42025-03-06-0.326-0.448-0.3470.000.001
2024Q32024-10-31-0.563-0.629-0.5700.800.421
2024Q22024-08-26-0.524--0.5031.410.88-
2023S12023-08-24-0.990-0.990-0.9905.065.061
2022S22023-03-09-1.077-0.900-1.0775.554.401
2022S12022-12-044.955-4.955193.7-1
2021S22022-03-15-0.979-1.040-0.9795.5210.001
2021S12021-12-04-1.117--1.2375.02-2
2021Q12021-05-04-0.618--0.6271.08--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.824-1.391-1.70521.6031.17
2020FY-2.747-1.680-2.67510.0732.12
2021FY-2.188-2.039-2.25010.4116.79
2022FY3.8513.7083.710206.23194.81
2023FY-2.091-2.260-2.1057.726.83
2024FY-1.879-1.983-1.8035.905.07
2025FY-2.114-2.015-2.1540.002.22
2026FY--1.709--0.00
2027FY--1.493--0.00
2028FY--1.546--0.00
2029FY--1.185--0.00
2030FY--0.992--45.96

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-292000.000.000.00
2026Q4S2026-09-032000.000.000.00
2026Q4S2026-08-251000.000.000.00
2026Q4S2026-06-211000.000.000.00
2026Q4S2026-05-132000.000.000.00
2026Q4S2026-03-132000.000.000.00
2026Q4S2026-02-021000.000.000.00
2026Q4R2026-10-29101-0.46-0.46-0.46
2026Q4R2026-08-25100-0.27-0.27-0.27
2026Q4E2026-10-30311-0.44-0.46-0.41
2026Q4E2026-10-29201-0.43-0.46-0.41
2026Q4E2026-10-11210-0.34-0.41-0.27
2026Q4E2026-10-03310-0.38-0.46-0.27
2026Q4E2026-09-15320-0.38-0.46-0.27

Estimate history

EPS, annual-1.24-1.788-1.705-2.675-2.253.71-2.105-1.803-1.992-1.6943
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.57-0.347-0.506-0.66-0.396-0.423-0.447-0.448-0.376
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual20.33610.58120.5119.95510.669198.527.8325.64300
Period201720182019202020212022202320242025TTM
Sales, quarterly0.78600000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual20.72421.04421.60129.14732.29336.04532.85436.86337.41238.335
Period201720182019202020212022202320242025MRQ
Shares, quarterly33.19436.86336.87537.39237.39937.41237.51138.30538.335
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.005.647.83198.5210.679.9620.5110.58
Cost of Goods Sold Incl. D&A2.482.58-------
Gross Profit-2.48-2.58-------
Selling, General and Administrative Excl. Other62.5664.1772.4773.1473.9277.2369.0254.9247.86
Research and Development45.9647.9552.9852.0051.0758.7457.2741.6738.19
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-65.05-66.75-69.51-68.00122.10-69.36-62.14-36.89-38.23
Interest Expense0.050.040.040.050.650.610.320.100.00
Unusual Expense-0.063.240.000.000.000.000.00--
Net Income Before Taxes-64.17-74.23-61.36-68.97123.40-69.76-66.88-36.50-37.84
Income Taxes0.010.000.000.000.000.00-0.010.020.00
Consolidated Net Income-64.17-74.23-61.37-68.97123.40-69.77-66.87-36.52-37.84
Net Income From Continuing Operations-64.17-74.23-61.37-68.97123.40-69.77-66.87-36.52-37.84
Net Income-64.17-74.23-61.37-68.97123.40-69.77-66.87-36.52-37.84
EPS (Recurring)-1.68-1.93-1.80-2.103.71-2.25-2.67-1.71-1.79
EPS (Basic, Before Extraordinaries)-1.69-1.99-1.80-2.103.80-2.25-2.67-1.71-1.79
EPS (Diluted)-1.69-1.99-1.80-2.103.71-2.25-2.67-1.71-1.79
EBITDA-62.56-64.17-66.82-65.31124.60-66.56-59.06-34.40-37.28
Non-Operating Income (Expense)0.88-4.208.19-0.921.950.21-4.420.490.38
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.954.233.684.764.323.802.662.013.12
Price To Earnings Ratio----1.65----
Price To Sales Ratio--28.6317.491.1055.74---
Operating Margin---1,231.73-868.2661.50-650.17-624.21-179.86-361.27
Net Margin---1,087.38-880.7062.16-653.94-671.70-178.03-357.66
Shares Outstanding38.3437.4136.8632.8536.0432.2929.1521.6021.04
Market Capitalization118.46118.46175.03137.33236.09619.35620.97--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.590.610.640.640.660.670.610.65
Gross Profit-0.59-0.61-0.64-0.64-0.66-0.67-0.61-0.65
Selling, General and Administrative Excl. Other14.2616.5816.5115.2114.2517.1117.3416.21
Research and Development10.1912.1612.0511.5610.4112.9513.2612.02
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-14.85-17.20-17.15-15.85-14.91-17.78-17.96-16.86
Interest Expense0.010.010.010.010.010.010.010.01
Unusual Expense0.000.000.00-0.060.143.160.000.00
Net Income Before Taxes-14.41-17.16-16.77-15.82-14.79-24.67-18.66-12.80
Income Taxes0.000.000.000.010.000.00-0.000.00
Consolidated Net Income-14.41-17.16-16.77-15.83-14.79-24.67-18.66-12.80
Net Income From Continuing Operations-14.41-17.16-16.77-15.83-14.79-24.67-18.66-12.80
Net Income-14.41-17.16-16.77-15.83-14.79-24.67-18.66-12.80
EPS (Recurring)-0.38-0.45-0.45-0.42-0.39-0.60-0.51-0.35
EPS (Basic, Before Extraordinaries)-0.38-0.45-0.45-0.42-0.40-0.66-0.51-0.35
EPS (Diluted)-0.38-0.45-0.45-0.42-0.40-0.66-0.51-0.35
EBITDA-14.26-16.58-16.51-15.21-14.25-17.11-17.34-16.21
Non-Operating Income (Expense)0.450.050.40-0.020.27-3.72-0.694.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.991.090.900.971.071.491.000.23
Price To Sales Ratio-----181.7457.2131.08
Shares Outstanding38.3438.3137.5137.4137.4037.3936.8736.86
Market Capitalization118.46145.17148.49163.01138.73140.86143.08175.03

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments117.46164.90222.05269.29145.76196.5398.19100.38144.75
Short Term Receivables1.641.222.071.6528.212.992.1352.361.18
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets3.184.124.544.416.231.642.872.790.32
Total Current Assets122.28170.24228.67275.35180.20201.16103.19155.53146.25
Net Property, Plant & Equipment6.604.636.757.828.9410.624.381.481.92
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.050.250.290.360.390.800.390.03
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets128.88174.93235.67283.46189.51212.17108.36157.39148.20
Short Term Debt Incl. Current Port. of LT Debt1.521.341.441.291.301.331.310.000.00
Accounts Payable1.180.750.491.085.343.172.082.140.73
Other Current Liabilities11.219.8115.2116.2744.7960.7426.1535.2613.78
Total Current Liabilities13.9211.9017.1318.6551.4365.2429.5437.4014.51
Long Term Debt3.081.352.903.955.326.831.320.000.00
Provision for Risks Charges10.285.386.022.767.4015.4711.255.794.12
Other Liabilities0.200.000.003.937.603.3210.3421.189.79
Total Liabilities27.4818.6426.0529.2871.7590.8752.4664.3728.42
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity101.40156.29209.62254.18117.75121.3055.9193.02119.78
Total Shareholders Equity101.40156.29209.62254.18117.75121.3055.9193.02119.78
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity101.40156.29209.62254.18117.75121.3055.9193.02119.78
Total Liabilities & Stockholders Equity128.88174.93235.67283.46189.51212.17108.36157.39148.20
Book Value Per Share2.714.246.387.053.654.162.594.425.78
Tangible Book Value Per Share2.714.246.377.043.644.152.554.405.78
Full-Time Employees149174182191177159147129119
Price to Book Ratio1.950.960.640.925.264.65---
Return on Assets-48.87-29.89-26.5752.18-34.74-41.72-27.48-24.77-15.69
Return on Equity-57.62-33.54-29.7466.36-58.37-75.47-49.04-35.57-20.39
Return on Invested Capital-71.05-38.93-32.4547.81-56.69-52.19-63.81-40.68-21.57
Quick Ratio8.7914.3113.3514.773.503.083.494.1610.08
Current Ratio8.7914.3113.3514.773.503.083.494.1610.08

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-64.41-74.23-61.37-68.97123.40-69.77-66.87-36.52-37.84
Depreciation2.492.582.692.692.502.813.082.480.94
Other Funds (Non Cash)5.5910.560.5211.575.065.479.563.86-5.89
Funds from Operations-56.35-61.10-58.15-54.71130.95-61.49-54.23-30.17-42.79
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.671.46-4.31-6.69-6.29-37.9223.9630.380.13
Cash from Operating Activities-58.02-59.64-62.46-61.40124.66-99.41-30.270.21-42.65
Capital Expenditures-0.20-0.86-0.82-0.90-1.48-1.43-1.79-1.88-0.89
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses-0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments27.7486.1441.9846.31-104.91-22.97-21.98-19.499.96
Purchase of Investments-23.49-79.81-272.57-309.16-313.50-97.21-78.20-76.47-30.89
Sale Or Maturity of Investments51.23165.94314.55355.47208.5974.2456.2256.9840.84
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities27.5485.2841.1645.41-106.40-24.40-23.77-21.369.08
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.130.0817.760.03-0.4056.61121.941.020.40
Repurchase of Common Pref Stock0.000.000.000.00-0.660.000.000.000.00
Sale of Common Pref Stock0.130.0817.760.030.2656.61121.941.020.40
Proceedsfrom Stock Options0.000.0017.710.000.0056.32121.040.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.00-0.00
Change in Long Term Debt0.000.000.000.000.000.000.00-0.00
Issuance of Long Term Debt0.000.000.000.000.000.000.00-0.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00-0.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities-1.39-1.3816.39-1.30-1.6455.32120.61-0.230.40
Exchange Rate Effect0.60-1.641.02-5.680.270.77-4.76-2.010.11
Net Change in Cash-31.2622.61-3.90-22.9616.89-67.7161.80-23.39-33.06
Free Cash Flow-58.21-60.50-63.26-62.04123.43-100.43-31.82-0.83-43.12
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow----1.77----
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments68.8684.2198.03117.46131.37143.83
Short Term Receivables1.881.662.881.642.644.53
Inventories0.000.000.000.000.000.00
Other Current Assets2.002.682.303.182.933.11
Total Current Assets72.7388.55103.20122.28136.94151.46
Net Property, Plant & Equipment4.535.295.896.604.004.62
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.010.01
Other Assets0.000.000.000.000.000.00
Total Assets77.2793.84109.09128.88140.95156.10
Short Term Debt Incl. Current Port. of LT Debt1.451.501.501.521.541.54
Accounts Payable1.442.192.402.232.672.48
Other Current Liabilities8.378.497.0510.1710.5512.19
Total Current Liabilities11.2712.1710.9513.9214.7616.20
Long Term Debt1.832.272.663.080.390.77
Provision for Risks Charges3.306.6210.0910.285.544.92
Other Liabilities0.190.200.200.200.200.20
Total Liabilities16.5921.2723.9027.4820.8922.10
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity60.6872.5885.19101.40120.06134.00
Total Shareholders Equity60.6872.5885.19101.40120.06134.00
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity60.6872.5885.19101.40120.06134.00
Total Liabilities & Stockholders Equity77.2793.84109.09128.88140.95156.10
Book Value Per Share1.581.892.272.713.213.58
Tangible Book Value Per Share1.581.892.272.713.213.58
Full-Time Employees-116.70-149-153
Price to Book Ratio1.951.701.461.361.040.97
Return on Assets-58.81-51.65-53.66-48.68-43.81-43.39
Return on Equity-71.01-62.49-62.64-57.39-49.84-48.88
Return on Invested Capital-23.06-22.92-19.09-15.15-12.28-18.30
Quick Ratio6.467.279.428.799.289.35
Current Ratio6.467.279.428.799.289.35

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-14.59-17.21-16.77-15.84-15.97-24.16
Depreciation0.600.610.640.640.680.66
Other Funds (Non Cash)1.141.181.272.001.974.05
Funds from Operations-12.87-15.42-14.87-13.20-13.32-19.45
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.181.96-3.19-0.260.544.27
Cash from Operating Activities-13.05-13.45-18.06-13.45-12.78-15.18
Capital Expenditures0.00-0.030.00-0.17-0.06-0.13
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00--0.00
Purchase or Sale of Investments-0.0818.13-5.1314.8214.6718.17
Purchase of Investments0.070.03-10.26-13.32-21.37-24.25
Sale Or Maturity of Investments-0.1518.115.1328.1436.0342.42
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.0818.11-5.1314.6414.6018.04
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.120.010.000.000.07
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.120.010.000.000.07
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.38-0.27-0.37-0.37-0.39-0.29
Exchange Rate Effect0.430.350.08-0.26-0.12-1.18
Net Change in Cash-13.084.74-23.480.561.321.39
Free Cash Flow-13.05-13.48-18.06-13.63-12.84-15.31

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 5.65M
Switzerland2024: 5.65M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.00%0.0M38.2M2.03K
2026-10-150.00%0.0M38.2M1.77K
2026-09-300.00%0.0M38.2M3.30K
2026-09-150.00%0.0M38.2M4.92K
2026-08-310.00%0.0M38.2M5.25K
2026-08-140.00%0.0M37.4M6.30K
2026-07-310.00%0.0M37.4M6.62K
2026-07-150.01%0.0M37.4M6.62K
2026-06-300.00%0.0M37.4M5.53K
2026-06-150.03%0.0M37.4M4.51K
2026-05-290.03%0.0M37.4M4.39K
2026-05-150.02%0.0M37.4M3.67K
2026-04-300.03%0.0M37.3M3.44K
2026-04-150.03%0.0M37.3M4.44K
2026-03-310.04%0.0M37.3M4.57K
2026-03-130.04%0.0M37.3M4.87K
2026-02-270.05%0.0M37.3M4.61K
2026-02-130.04%0.0M37.3M4.51K
2026-01-300.04%0.0M37.3M7.07K
2026-01-150.04%0.0M37.3M6.17K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-30SEC
2026-08-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-07-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-16SEC
2026-07-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-06SEC
2026-07-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-02SEC
2026-06-24S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-30SEC
2026-05-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC
2026-05-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-01SEC
2026-04-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-14SEC
2026-03-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC
2026-03-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-12SEC
2026-03-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-31SEC
2026-03-1220-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-02-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-02SEC
2026-01-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-11SEC
2025-12-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-07SEC
2025-11-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-11-12SEC
2025-10-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-09-30SEC
2025-08-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-06-30SEC
2025-07-17SCHEDULE 13GSEC
2025-06-25S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2025-06-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-06-12SEC
2025-05-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-03-31SEC
2025-05-02SCHEDULE 13GSEC
2025-04-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-04-29SEC
2025-04-24EFFECTEffectiveness filing by commission orderSEC
2025-04-22CORRESPSEC
2025-04-21UPLOADUpload SubmissionSEC
2025-04-11F-3Registration statement for specified transactions by certain foreign private issuersSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
MONTANOVA CAPITAL, LLC5.92%
BVF INC/IL3.61%
CITADEL ADVISORS LLC0.05%
MORGAN STANLEY0.00%
UBS Group AG0.00%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.00%
Avantis International Equity ETF0.00%

OakChart. MOLN. Cached 15 minutes.

Some panels did not load: insider.